CLL Smart 1: Flow Cytometry (FCM) CLL Panel and FISH for 17p

FCM CLL Panel uses flow cytometry to detect abnormal lymphocytes. It helps in diagnosing CLL and can differentiate it from other lymphoproliferative disorders. It also provides information about the expression of different surface markers on lymphocytes.

The 17p deletion involves the loss of the TP53 gene which is important for controlling cell division and apoptosis. Patients with the 17p deletion typically have a more aggressive disease course and are often resistant to standard chemotherapy.

A blood sample is taken from the patient. Flow Cytometry is used to analyze surface markers on lymphocytes, and FISH is used to detect the 17p deletion by using fluorescent probes that bind to parts of the chromosomes.

If the 17p deletion is detected, it means that CLL may have an aggressive course and that standard chemotherapy may not be effective. It indicates the need for alternate treatment strategies.

There are no special preparations needed for this test. It is, however, advisable to inform your doctor about any medications or supplements you are taking.

Yes, this test can be used to monitor the progression of CLL, especially if it was found to have the 17p deletion. It helps in monitoring how the disease is responding to the treatment and if there are any changes in the cancer cells.

Patients with the 17p deletion may be treated with targeted therapies such as ibrutinib or a combination of drugs, instead of standard chemotherapy. Stem cell transplantation might be another option for some patients.

CLL is not considered curable with the current treatments available. However, with appropriate treatment, many individuals with CLL can manage the disease as a chronic condition.

There is no known way to prevent CLL. The risk of developing CLL is associated with age, family history, and exposure to certain chemicals.

Common symptoms of CLL include fatigue, swollen lymph nodes, weight loss, frequent infections, and easy bruising or bleeding.

The frequency of this test is based on the doctor’s recommendations, usually at diagnosis and at various points during treatment, especially if there’s a change in health status or if considering a stem cell transplant.

In case of abnormal values, a hematologist or an oncologist should be consulted. They specialize in blood disorders and cancer respectively.

A healthy lifestyle is important in managing CLL. This includes a balanced diet, regular exercise, and avoiding tobacco and excessive alcohol. Stress management is also important.

Understanding the nature of Chronic Lymphocytic Leukemia, particularly in the context of the 17p deletion, can be fundamental in managing the condition effectively. The CLL Smart 1 test is an essential tool that aids in diagnosis, monitoring, and guiding treatment decisions. Keeping an open dialogue with your doctor, understanding the results, and complying with the prescribed treatment regimen is integral in navigating CLL.